Isofols appoints Sven Erickson as Chief Commercial Officer
In preparation for partnering negotiations with pharma companies Isofol Medical AB (publ) announces the appointment of Sven Erickson as Chief Commercial Officer. Mr. Erickson is an experienced life Science executive and brings to Isofol a track record of success in commercialization of pharmaceuticals, international license deals and marketing, spanning more than two decades.
Isofol Medical AB (publ), a clinical stage oncology company about to enter a registration study within first line colorectal cancer treatment, announces the appointment of Sven Erickson as Chief Commercial Officer. He will lead the licensing and commercialization efforts of the company’s lead candidate Modufolin®. Mr. Erickson is a life Science executive with over 20 years’ experience from research, clinical development and successful commercialization of diagnostics and pharmaceuticals, especially in the oncology field. With a strong track record of negotiating international license deals, Mr. Eriksson will be an important driving force behind the commercialization of Modufolin® and the company’s partnering efforts in preparations of a potential market approval.
Anders Rabbe, CEO of Isofol, says “Sven’s appointment is in line with Isofol’s strategy to bolstering our commercial and partnering capabilities as the pivotal study of Modufolin® draws closer. His consistent, successful track record and strong business expertise will ensure that Modufolin® reaches a favorable licensing agreement and strong presence at future partnering and scientific conferences. It’s with great pleasure I can welcome Sven to Isofol during these exciting times ”
Prior to joining Isofol, Mr. Erickson served as Director of Medical Affairs in the Nordic region at PTC Therapeutics. Preceding his employment at PTC Therapeutics was his role as Product Search and Evaluation Manager at Medivir, a research-based pharmaceutical company with focus on oncology, managing in-licensing operations. Before joining Medivir in 2014, Mr. Erickson also held different positions at Novartis including Scandinavian Medical Head Critical Care. Mr. Eriksson is a PhD in Experimental Oncology from The Karolinska Institute, Sweden.
“I’m more than excited to join Isofol and its great team,” said Dr. Erickson, “and I am looking forward to put Modufolin ® at the top of the mind of potential collaborators and, ensure in time, the commercialization of Modufolin®.”
For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB
Email: anders.rabbe@isofolmedical.com
Phone: +46 (0)707 646 500
About Modufolin®
Modufolin® (active ingredient [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. As Modufolin® does not require metabolic activation to exert its effect, Modufolin® is suitable for all patients irrespective of their capacity to activate folates. Modufolin® is currently being evaluated in a clinical Phase II study.
About Isofol Medical AB
Isofol Medical AB is a clinical stage oncology company developing Modufolin® as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Through a worldwide exclusive license agreement, Isofol Medical holds the rights to commercialise Modufolin® with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the NASDAQ First North Premier. Certified Adviser is FNCA Sweden AB.
